CN102232073B - Ssao活性抑制剂 - Google Patents

Ssao活性抑制剂 Download PDF

Info

Publication number
CN102232073B
CN102232073B CN200980136970.1A CN200980136970A CN102232073B CN 102232073 B CN102232073 B CN 102232073B CN 200980136970 A CN200980136970 A CN 200980136970A CN 102232073 B CN102232073 B CN 102232073B
Authority
CN
China
Prior art keywords
imidazo
pyridine
alkyl
tetrahydrochysene
nitrae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980136970.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102232073A (zh
Inventor
E·萨沃里
M·希金博特姆
K·奥利弗
A·V·A·霍根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boshan Artificial Intelligence Cambridge Co ltd
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN102232073A publication Critical patent/CN102232073A/zh
Application granted granted Critical
Publication of CN102232073B publication Critical patent/CN102232073B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980136970.1A 2008-09-16 2009-09-16 Ssao活性抑制剂 Expired - Fee Related CN102232073B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0801979-6 2008-09-16
SE0801979 2008-09-16
US10673408P 2008-10-20 2008-10-20
US61/106,734 2008-10-20
PCT/EP2009/062011 WO2010031789A1 (en) 2008-09-16 2009-09-16 New compounds i

Publications (2)

Publication Number Publication Date
CN102232073A CN102232073A (zh) 2011-11-02
CN102232073B true CN102232073B (zh) 2014-10-29

Family

ID=41226693

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980136970.1A Expired - Fee Related CN102232073B (zh) 2008-09-16 2009-09-16 Ssao活性抑制剂

Country Status (15)

Country Link
US (7) US8263616B2 (cg-RX-API-DMAC7.html)
EP (1) EP2334672B1 (cg-RX-API-DMAC7.html)
JP (1) JP5539989B2 (cg-RX-API-DMAC7.html)
CN (1) CN102232073B (cg-RX-API-DMAC7.html)
AU (1) AU2009294660B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0918602B8 (cg-RX-API-DMAC7.html)
CA (1) CA2737527C (cg-RX-API-DMAC7.html)
DK (1) DK2334672T3 (cg-RX-API-DMAC7.html)
EA (1) EA019167B1 (cg-RX-API-DMAC7.html)
ES (1) ES2440279T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011002581A (cg-RX-API-DMAC7.html)
NZ (1) NZ592238A (cg-RX-API-DMAC7.html)
PL (1) PL2334672T3 (cg-RX-API-DMAC7.html)
PT (1) PT2334672E (cg-RX-API-DMAC7.html)
WO (1) WO2010031789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263616B2 (en) 2008-09-16 2012-09-11 Proximagen Ltd 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
SG11201400277VA (en) 2011-09-14 2014-05-29 Proximagen Ltd New enzyme inhibitor compounds
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201416444D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New compounds
GB201416446D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
JP6489203B2 (ja) 2015-03-02 2019-03-27 日本電気株式会社 受信機器、および復号・提示方法
GB201507031D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd New pharmaceutical salt forms
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201513115D0 (en) * 2015-07-24 2015-09-09 Proximagen Ltd New therapeutic compound and use in therapy
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
AU2016366635A1 (en) * 2015-12-07 2018-06-21 Benevolentai Cambridge Limited VAP-1 inhibitors for treating pain
GB201618029D0 (en) * 2016-10-25 2016-12-07 Proximagen Ltd New process
WO2020139988A1 (en) * 2018-12-28 2020-07-02 Forma Therapeutics, Inc. Compositions for inhibiting ubiquitin specific protease 1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038163A1 (en) * 2000-11-13 2002-05-16 El Gendler Bone putty and method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) * 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
JPS5285191A (en) * 1976-01-07 1977-07-15 Farmaceutici Italia Novel 4*5*6*77tetrahydroimidazoo *4*55c*pyridine derivative process for preparing same and medicine having antiiulcer antiisecretion and antiicolline activities containing same
IT1098015B (it) * 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2002038153A1 (en) * 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
SE0004101D0 (sv) * 2000-11-09 2000-11-09 Pharmacia Ab New use
US8263616B2 (en) 2008-09-16 2012-09-11 Proximagen Ltd 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038163A1 (en) * 2000-11-13 2002-05-16 El Gendler Bone putty and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Anti-ulcer and Antisecretory Activity of Selected Imidazopiperidines;G.Arcari,et al.;《Arzneimittel-Forschung》;19841231;第34卷(第11期);1467-1471 *

Also Published As

Publication number Publication date
US8263616B2 (en) 2012-09-11
EP2334672B1 (en) 2013-11-20
EA019167B1 (ru) 2014-01-30
US20190359611A1 (en) 2019-11-28
HK1159102A1 (en) 2012-07-27
US20150218161A1 (en) 2015-08-06
CN102232073A (zh) 2011-11-02
US10399973B2 (en) 2019-09-03
US20120302583A1 (en) 2012-11-29
JP2012506368A (ja) 2012-03-15
EP2334672A1 (en) 2011-06-22
US11040969B2 (en) 2021-06-22
PL2334672T3 (pl) 2014-03-31
CA2737527A1 (en) 2010-03-25
DK2334672T3 (da) 2013-12-02
NZ592238A (en) 2012-11-30
MX2011002581A (es) 2011-04-07
AU2009294660B2 (en) 2013-11-14
WO2010031789A1 (en) 2010-03-25
US20170044157A1 (en) 2017-02-16
US20180118744A1 (en) 2018-05-03
JP5539989B2 (ja) 2014-07-02
US9890160B2 (en) 2018-02-13
ES2440279T3 (es) 2014-01-28
AU2009294660A1 (en) 2010-03-25
BRPI0918602B8 (pt) 2021-05-25
US20110207746A1 (en) 2011-08-25
US20140121219A1 (en) 2014-05-01
BRPI0918602A2 (pt) 2015-12-15
US9035066B2 (en) 2015-05-19
CA2737527C (en) 2015-12-29
EA201100391A1 (ru) 2011-10-31
US8569338B2 (en) 2013-10-29
PT2334672E (pt) 2014-01-02
BRPI0918602B1 (pt) 2020-04-07
US9493457B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
CN102232073B (zh) Ssao活性抑制剂
EP2376490B1 (en) Imidazopyridine compounds
JP5613671B2 (ja) 新規化合物ｉｉ
JP5643347B2 (ja) 新規酵素阻害化合物
WO2006088246A1 (ja) Ｇｐｒ３４受容体機能調節剤
CN113993845A (zh) 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
WO2020257261A1 (en) SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS
HK1159102B (en) Inhibitors of ssao activity
HK40062458A (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
HK1195065A (en) New enzyme inhibitor compounds
HK1219071B (en) New compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1159102

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1159102

Country of ref document: HK

CP01 Change in the name or title of a patent holder

Address after: London, England

Patentee after: Boshan Artificial Intelligence Cambridge Co.,Ltd.

Address before: London, England

Patentee before: PROXIMAGEN LTD.

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

Termination date: 20210916

CF01 Termination of patent right due to non-payment of annual fee